Will Glaxo’s peers follow its anti-corruption lead in China?

Carly Helfand GlaxoSmithKline, post-corruption scandal, has been working hard to clean up its act in China, overhauling its sales practices to wipe out bribery–and its general ...

Mylan latest caught up in DOJ probe of generic drug prices

Eric Palmer Mylan said today that it got a special delivery from the Justice Department Thursday, making it the most recent of a string of drugmakers to get a subpoena from federal ...

Novartis keeps its CAR-T lead with positive Phase II data

Damian Garde Novartis, leading a pack of companies developing genetically engineered T cells to fight cancer, unveiled more promising data on its Phase II treatment as it wends toward ...

Chinese advisers push for tougher generics quality standards

Carly Helfand China's political advisers are encouraging domestic generic drug development–but at the same time, they're also pushing for tougher quality standards. On ...

Amgen takes to Europe with its Humira biosimilar

Damian Garde Amgen submitted its copy of AbbVie's blockbuster Humira to European regulators, angling to siphon revenues from the world's top-selling drug as rivals develop biosimilars ...

Teva to divest $1B in assets to clear antitrust hurdles to Allergan deal: Reuters

Carly Helfand Back in July, Teva agreed to pick up Allergan's generics business for $ 40.5 billion. To get that deal past regulators, though, it's going to have to divest some ...

Startup raises $15M to turn an old diabetes drug into a potent cancer killer

Damian Garde A group of scientists at UCLA have cooked up some compounds that could harness the cancer-fighting properties of metformin while avoiding the biological hurdles that have ...

Lilly backs a $25M round for anti-inflammatory startup Symic

Damian Garde San Francisco's Symic raised $ 25 million to fund its work on a pair of anti-inflammatory medicines targeting the extracellular matrix, recruiting Eli Lilly to lead ...

Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti

Carly Helfand After winning FDA approval Monday, the latest multiple myeloma treatment–Empliciti, from Bristol-Myers Squibb and AbbVie–is about to hit the scene. And like ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS